Can transdiagnostic CBT improve outcomes in children with ASD?

By Jessica K. Edwards

Transdiagnostic interventions apply the same underlying treatment principles across mental disorders, without any tailoring to a specific diagnosis. Essentially, these interventions are applicable to people who have a range of DSM-5 diagnoses, as different emotional responses from the same cues are addressed.¹ Children with autism spectrum disorder (ASD) typically exhibit a spectrum of mental health problems, including internalizing and externalizing symptoms. This characteristic raises the issue as to whether a transdiagnostic treatment approach might be effective in these patients.

To address this question, researchers in Canada examined the efficacy of a manual and individually delivered 10-session transdiagnostic cognitive behavioural therapy (tCBT) treatment aimed at improving emotional regulation and mental health difficulties in children with ASD. Based on informant (parent and clinician) reports, children receiving tCBT (n = 35) demonstrated significant improvements in aspects of emotional regulation and psychopathology compared to waitlist controls (n = 34). These improvements were maintained at 10-weeks follow-up. These data suggest that CBT might be adapted to move beyond addressing anxiety-specific domains to concomitantly target multiple emotional problems in children with ASD.

Referring to:

References:

Glossary:
Transdiagnostic cognitive behavioural therapy: the transdiagnostic paradigm is founded on the concept that many mental health disorders share common etiological and maintenance processes. When applied to cognitive behavioural therapy, patients are encouraged to manage their underlying emotional regulation, anxiety, mood and externalizing issues by changing the way they think and behave.
Data from randomized controlled trials (RCTs) support that cognitive-behavioural therapy (CBT), selective serotonin reuptake inhibitor (SSRI) treatment (Sertraline) and a combination of both are effective at treating anxiety disorders. How these evidence-based treatments exert their effects, however, is unknown. In 2019, Matti Cervin and colleagues analysed data from the largest RCT for paediatric anxiety disorders to examine how these treatments affect different domains of anxiety (i.e., anxiety severity, frequency, manifestations, and avoidance strategies).

In their unique approach, Cervin et al. conceptualized youth anxiety as a network of interconnected nodes, with each node corresponding to one aspect of anxiety. They then analyzed which aspects of this anxiety network were directly affected by evidence-based treatments for youth anxiety. Consistent with prior studies, the researchers found that combined CBT with the SSRI sertraline had strong effects on the anxiety network over placebo treatment. These treatments seemed to predominantly attenuate the severity of anxiety feelings and impairments in the home setting. No direct effects were found in relation to impairments outside of the home, such as at school.

"Current treatments might be improved by collaborating more with school personnel and by thoroughly assessing how a young individual with anxiety is affected in school", explains Cervin. “Although we analyzed data from the largest treatment study conducted to date, we still need to see whether our results replicate; if they do, then treatment strategies that readily address anxiety-associated school impairments should be developed and tested".

References:

Glossary:
Randomized controlled trial: an experimental setup whereby participants are randomly allocated to an intervention/treatment group or a control/placebo group; randomization of participants occurs after assessments for eligibility, and is used to minimize selection bias.

Cognitive-behavioural therapy: a form of talking therapy that encourages patients to manage their psycho-social problems by changing the way they think and behave; CBT focuses on current problems and finds practical ways to improve state-of-mind on a day-by-day basis.

Selective serotonin reuptake inhibitors: a class of drug that is typically used as an antidepressant in the treatment of anxiety or major depressive disorders. These drugs increase circulating serotonin levels by limiting its reabsorption into the cell; the effect is an increased level of serotonin available to bind postsynaptic receptors and increased serotonin-mediated neurotransmission.

Referred to:

See also: